quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:00:00·48d
PRRelease
Equifax Inc. logo
Neurocrine Biosciences Inc. logo

BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)

EFX· Equifax Inc.NBIX· Neurocrine Biosciences Inc.
FinanceHealth Care
Original source

Companies

  • EFX
    Equifax Inc.
    Finance
  • NBIX
    Neurocrine Biosciences Inc.
    Health Care

Recent analyst ratings

  • Apr 16EFXUpdateMizuho$222.00
  • Feb 24NBIXUpdateWolfe Research$160.00
  • Feb 17EFXUpdateBofA Securities$250.00
  • Jan 8NBIXUpdateMorgan Stanley$175.00
  • Oct 21NBIXUpdateCitigroup$175.00
  • Oct 13EFXUpdateOppenheimer$271.00

Related

  • PR1d
    Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
  • SEC2d
    SEC Form 10-Q filed by Equifax Inc.
  • SEC2d
    SEC Form S-3ASR filed by Equifax Inc.
  • SEC2d
    Equifax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR2d
    Equifax Delivers Record First Quarter Revenue - $37 Million Above Midpoint of February Guidance
  • ANALYST7d
    Mizuho initiated coverage on Equifax with a new price target
  • SEC8d
    SEC Form DEFA14A filed by Neurocrine Biosciences Inc.
  • SEC8d
    SEC Form DEF 14A filed by Neurocrine Biosciences Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022